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Background: Chronic venous insufficiency (CVI) represents a major global health problem with increasing
prevalence and morbidity. CVI is due to an incompetence of the venous valves, which causes venous reflux and
distal venous hypertension. Several studies have focused on the replacement of diseased venous valves using
xeno- and allogenic transplants, so far with moderate success due to immunologic and thromboembolic
complications. Autologous cell-derived tissue-engineered venous valves (TEVVs) based on fully biodegrad-
able scaffolds could overcome these limitations by providing non-immunogenic, non-thrombogenic constructs
with remodeling and growth potential.
Methods: Tri- and bicuspid venous valves (n = 27) based on polyglycolic acid–poly-4-hydroxybutyrate com-
posite scaffolds, integrated into self-expandable nitinol stents, were engineered from autologous ovine bone-
marrow-derived mesenchymal stem cells (BM-MSCs) and endothelialized. After in vitro conditioning in a
(flow) pulse duplicator system, the TEVVs were crimped (n = 18) and experimentally delivered (n= 7). The
effects of crimping on the tissue-engineered constructs were investigated using histology, immunohistochem-
istry, scanning electron microscopy, grating interferometry (GI), and planar fluorescence reflectance imaging.
Results: The generated TEVVs showed layered tissue formation with increasing collagen and glycosamino-
glycan levels dependent on the duration of in vitro conditioning. After crimping no effects were found on the
MSC level in scanning electron microscopy analysis, GI, histology, and extracellular matrix analysis. However,
substantial endothelial cell loss was detected after the crimping procedure, which could be reduced by in-
creasing the static conditioning phase.
Conclusions: Autologous living small-diameter TEVVs can be successfully fabricated from ovine BM-MSCs
using a (flow) pulse duplicator conditioning approach. These constructs hold the potential to overcome the
limitations of currently used non-autologous replacement materials and may open new therapeutic concepts for
the treatment of CVI in the future.
Introduction
Lower extremity chronic venous insufficiency (CVI)displays a global health problem with a substantial so-
cioeconomic impact.1–3 CVI describes the endpoint of dif-
ferent pathological disorders of the venous system resulting
in venous valve insufficiency associated with venous blood
reflux, obstruction, stasis, and distal venous hypertension.1,4
This valvular incompetence can be caused by congenital
defects, structural weakness, or abnormally distensible ve-
nous walls due to other pathologies.5 If left untreated, then
this results in pain, swelling, significant edema, sclerosis,
skin changes, and ulcerations.1
For a long time, CVI has been treated conservatively using
various compression techniques and devices6 or—in case of
superficial lesions—surgically by ligation of the sapheno-
femoral junction and stripping of the saphenous vein.5 In cases
of deep vein insufficiency, recently percutaneous transcatheter
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valve repair has been investigated as part of first in-man
clinical trials using bioprosthetic stented valves. In spite of the
initially good performance and the extended anticoagulation
protocols, the xenogenic glutaraldehyde-fixed valves showed
excessive neo-intimal hyperlasia and fibrotic transformation in
the long-term follow-up groups. This resulted in valve in-
competence and/or valvular stenosis in up to 90% of patients
and—up to now—none of the used prostheses qualified for
routine clinical use.7
Tissue engineering is aiming at the generation of living
autologous substitutes with the potential for remodeling,
regeneration, and growth that might overcome the limita-
tions of currently used artificial animal-derived valve sub-
stitutes. After biomimetic conditioning of the constructs in
the bioreactor, these living constructs are endothelialized in
order to provide an antithrombogenic surface that is resistant
to thromboembolic complications as reported for current
artificial valve prostheses.8,9 Tissue-engineered valvular
substitutes for diseased heart valves have been extensively
investigated in vitro10–13 and in vivo14–16 with first-
promising results. Besides the field of heart valve disease,
also in insufficient venous valves, a living autologous tissue-
engineered replacement could restore valvular integrity and
function. Importantly, it may hold the potential to overcome
the limitations of currently used replacement materials in-
cluding progressive calcific valvular degeneration as well as
clotting activation. However, for a possible future clinical
realization of the venous valve tissue engineering concept,
these valves would have to fulfill two main criteria: (1) they
would have to tolerate the potentially harmful crimping
procedure associated with transcatheter valve delivery ap-
proaches, and (2) they would have to be fabricated from an
easily accessible, ‘‘minimally invasive’’ cell source to cir-
cumvent the necessity of harvesting intact donor structures.
In a recent investigation14 we created tissue-engineered
heart valves (TEHVs) from bone-marrow-derived mesen-
chymal stem cells as well as blood-derived endothelial pro-
genitor cells. These TEHVs were successfully implanted into
the orthotopic valve position of a large animal model using a
minimally invasive transcatheter (transapical) approach. This
study was followed by a similar approach using bone marrow
mononuclear cells in a clinically relevant large animal mod-
el16 as well as in the high-pressure environment.17 The fab-
rication of autologous cell-based tissue-engineered venous
valves (TEVVs) raises significant challenges in the light of
the miniaturized dimensions of native venous valves.
Therefore, the present study investigates the principal
feasibility of fabricating autologous living (ovine) bone-
marrow-derived mesenchymal stem cell–based TEVV
substitutes in vitro, applicable to minimally invasive
(transcatheter) implantation techniques. Moreover, we in-
vestigate the macro- and microstructural changes of differ-
ent cellular compartments of TEVVs during the processes of
in vitro crimping as well as experimental delivery.
Materials and Methods
Cell harvest and isolation
Ovine mesenchymal stem cells (MSCs) were harvested
according to standardized protocols13,14 from bone marrow
aspirates of adult Swiss Alpine sheep. For this purpose bone
marrow was harvested from sheep under general anesthesia
into a heparinized syringe (n= 3). All procedures were
performed following ethical permission by the cantonal
veterinary commission [CVO-137-2009]. In brief, the
mononuclear cell (MC) fraction was isolated using a Histo-
paque 10771-density gradient (Sigma Chemical Co.). For
this purpose the heparinized bone marrow aspirate was
layered onto the Histo-paque and filled up with phosphate-
buffered saline (PBS, Sigma). After 30min of centrifugation
the MCs were isolated and washed with PBS. After isola-
tion, MCs were cultured in a-MEM (Ref. 22561; Gibco,
Life Technologies). All media were supplemented with 10%
fetal bovine serum (Invitrogen Corp.), 1% pen/strep (100U/
mL penicillin, 100mg/mL streptomycin; Sigma Chemical
Co.), 1% Amphotericin B (25 ng/mL Amphotericin B; Sig-
ma Chemical Co.), and 1% Glutamax (Gibco, Inc.). After
48 h of in vitro culture the nonadherent cell fraction was
removed and the cells were expanded up to passage 6 for
seeding onto the composite polymer scaffolds.
Phenotyping of cells
Isolated cells were characterized using immuno-
flourescence staining. Primary antibodies used for charac-
terization of mesenchymal stem cells were against CD29
(anti-ovine CD29; A. Zannetino), Stro4 (anti-ovine
STRO-4; A. Zannetino), CD44 (Santa Cruz, Inc.), CD166
(BioLegend), and CD31 (anti-ovine; BioLegend). En-
dothelial cells (ECs) were characterized using an antibody
against vWF (anti-human; Abcam). Alexa 546 phalloidin
(Invitrogen, Inc.) and DAPI (Sigma-Aldrich) were used as
control staining. Primary antibodies were detected with
Cyanine-2 goat-anti-mouse secondary antibodies ( Jackson
Immunoresearch Laboratories, Inc.).
For immunofluorescence stainings cells were first washed
with PBS and then fixed with 4% paraformaldehyde in PBS
for 10min. Following a second washing phase (PBS), cells
were permeabilized in 0.2% Triton X-100/PBS for 10min
and washed again three times in PBS. After blocking with
5% goat serum and 1% bovine serum albumin in PBS for
30min, primary antibodies were added and incubated for 1 h
at room temperature. After three washing steps with PBS,
secondary antibodies were added for 45min at room tem-
perature. The specimens were washed again three times in
PBS for 5min and mounted in commercially available
embedding medium (Aqua-Polymount, Polysciences, Inc.).
In addition, immunohistochemistry was performed using the
Ventana Benchmark automated staining system (Ventana
Medical Systems) and antibodies for alpha smooth muscle
actin (a-SMA, clone 1A4; Sigma-Aldrich), Desmin (clone
D33; DakoCytomatation), Vimentin (mM-anti-human Vi-
mentin; clone Vim 3B4), and vWF (Dako, Inc.). Analysis of
the stained sections and cells was carried out using an in-
verted fluorescence microscope equipped with a CCD
camera (ZEISS Axiovert 40 CFL and ZEISS Axioplan II;
Carl Zeiss AG). Image processing was performed using the
Microsoft Office Picture Manager (Microsoft).
Flow cytometric analysis
For the purpose of flow cytometry analyses, the in vitro-
cultured ovine bone-marrow-derived MSCs (BM-MSCs)
were harvested from the culture plates using Accutase
(Gibco, Life Technologies) and washed with PBS. Then,
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the cells were fixed in 2% paraformaldehyde (P6148; Sig-
ma-Aldrich) for 20min and washed in PBS. The cells were
subsequently permeabilized in BD Perm Buffer III (558050;
BD Biosciences) on ice for 30min and then washed in PBS
supplemented with 2% fetal calf serum (FCS). The cells
were then incubated with primary antibodies for 45min on
ice, washed twice, and incubated with the secondary anti-
body for another 45min on ice. Following washing, the
cells were resuspended in PBS+ 2% FCS and analyzed us-
ing BD FACSCanto II flow cytometry analyzer (Beckton-
Disckinson). The antibodies used were the following: Stro-4
(anti-ovine STRO-4; A. Zannettino), CD44 (anti-human
Santa Cruz, Inc.), CD166 (BioLegend), CD31 (Dako), IgG1
(BioLegend), and Cy2 secondary antibody anti-mouse
( Jackson Immunoresearch Laboratories, Inc.). Acquired
flow cytometry data were analyzed and processed using
FlowJo software (TreeStar, Inc.).
Scaffold fabrication
Diminutive bi- or trileaflet venous valve scaffolds (n = 24)
were fabricated from nonwoven polyglycolic acid (PGA)
meshes as previously described15,16 (thickness 1.0mm;
specific gravity 70mg/cm3; Cellon) and coated with 1.75%
poly-4-hydroxybutyrate (P4HB; TEPHA, Inc.) by dipping
into a tetrahydrofuran solution (Sigma Aldrich, Inc.). After
solvent evaporation, physical bonding of adjacent fibers and
continuous coating was achieved. P4HB is a biologically
derived, rapidly degradable polymer, which besides being
strong and pliable is thermoplastic (61C) and can be mol-
ded into three-dimensional shapes. The scaffolds were in-
tegrated into radially self-expandable nitinol stents
(length = 10.0mm; OD= 12.0mm when fully expanded at
37C; OptiMed) by attaching the scaffold matrix to the inner
surface of the nitinol stent wires using single interrupted
sutures (Polypropylene; Ethicon). After vacuum drying for
24 h, the scaffolds were sterilized using two different pro-
tocols: (1) by using ethylene oxide (EtO) gas sterilization
(the EtO was allowed to evaporate for 4 days to prevent
cytotoxicity.), or (2) by dipping the valves into a 70% eth-
anol solution for 2 h followed by an overnight exposure to
UV light. Next the scaffolds were preincubated in a-MEM
(Gibco, Life Technologies) with supplements for 12–24 h to
facilitate cell attachment.
Cell seeding
Ovine MSCs were seeded onto diminutive bi- or trileaflet-
shaped PGA-P4HB composite scaffolds using different
cell seeding numbers (groups: *1.5/3.0/4.5/5.0/7.0· 106
cells/cm2; n = 27) using fibrin as a cell carrier (Sigma Che-
mical Co.). Fibrinogen (10mg/mL of active protein) and
thrombin were prepared depending on the seeding protocol
used and titrated to an optimal clotting time of *30 s by
adapting the concentration of fibrinogen. The fibrinogen-
thrombin seeding procedure was performed using two dif-
ferent techniques: (1) by seeding cells resuspended in the
thrombin solution and subsequent sealing using fibrinogen
(n = 11 patches, thrombin concentration: 115.7 IU/mL) as
previously published,18 or (2) by seeding the cells re-
suspended in a fibrinogen-thrombin cosolution (n= 15 pat-
ches, thrombin concentration: 10 IU/mL) as previously
described.19 After static incubation of seeded constructs in
a-MEM (Sigma Chemical Co.; 10% fetal bovine serum
[FBS]; pen/strep and Amphotericin-B supplement) for short
periods (1, 4, or 7 days), they were placed into an inverted-
flow bioreactor system with diastolic (flow) pulse stimula-
tion mimicking the native cardiovascular environment. For
dynamic conditioning the medium was supplemented with
0.9mM of L-ascorbic acid-2-phosphate (Sigma Chemicals,
Inc.). The pulsatile flow was slightly increased over the
study period (from 1.5mL/min flow to 3mL/min flow) and
a-MEM was exchanged every 3–4 days. The constructs
were harvested after 1–2 or 11–14 days of dynamic condi-
tioning. After harvesting from the bioreactor, the constructs
were (1) endothelialized (n = 11; see the ‘‘Endothelialization
and crimping analysis’’ section) followed by further static
conditioning in EGM-2 (Lonza) medium, and (2) exposed
to a crimping procedure (n = 18) or analyzed immediately.
Endothelialization and crimping analysis
ECs were isolated according to previously published pro-
tocols.14 Briefly, the ovine blood vessels were flashed with
PBS and incubated for 30min in collagenase (2mg/mL,
Collagenase A; Roche Diagnostics GmbH). After incuba-
tion, the cell suspension was flushed out with EBM-2 me-
dium (EBMTM; Lonza, Inc.), and cultured on six-well
plates until confluency and expanded. The medium was
supplemented with 2% FBS, vascular endothelial growth
factor, human fibroblast growth factor, human recombinant
long-insulin-like growth factor-1, human epidermal growth
factor, gentamycin and amphotericin (GA-1000), hydro-
cortisone, heparin, and ascorbic acid. For endothelialization,
TEVV leaflets were seeded with 0.6–1.3 · 106 cryopre-
served ovine ECs per cm2. The constructs were cultured for
48 h in endothelial medium (EGM -2; Lonza Group AG;
Medium B constructs) to ensure adequate attachment of the
cells. Prior to seeding, ovine ECs were labeled using
carboxyfluorescein-diacetate-succinimidyl-ester at a con-
centration of 25 mM according to the manufacturers’ in-
structions (CFSE, CellTrace; CFSE Cell Proliferation Kit,
C34554; Invitrogen Corp.). After static incubation the con-
structs were crimped for *10min (n= 15 leaflets) to a size
of 16 F (*5mm) using a customized crimping machine
(Edwards LifeSciences, Inc.). Using the IVIS Imaging
System (PerkinElmer Life Sciences, Inc.), CFSE-labeled
ovine EC-seeded TEVVs were scanned before and after
crimping and the changes of fluorescence (counts) were
determined. For detection of CFSE-labeled ECs pre- and
postcrimping (CellTrace, CFSE Cell Proliferation Kit,
C34554; Invitrogen Corp.) a band-pass filter from 445 to
490 nm and a long-pass filter over 515 nm for excitation and
emission light, respectively, were used. The fluorescence
was detected by a CCD camera. The data were analyzed
using the Living Image software (Living Image 3.2;
PerkinElmer Life Sciences, Inc.). For assessment of the
location and density of seeded ECs on the surface, the
constructs were scanned using a StereoLumar.V12 stereo-
microscope (Carl Zeiss).
Qualitative tissue analysis
The tissue composition of TEVV constructs was analyzed
qualitatively using immunohistochemistry and/or histology
and compared with native ovine venous valve leaflets
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(jugular vein and saphenous vein valve leaflets). The tissue
sections were studied using hematoxylin and eosin (H&E)
and Masson–Trichrome stainings. In addition, immunohis-
tochemistry was performed using the Ventana Benchmark
automated staining system (Ventana Medical Systems) and
antibodies for a-SMA (clone 1A4; Sigma-Aldrich), Desmin
(clone D33; DakoCytomatation), and Vimentin (clone
VIM3B4; DakoCytomatation). All sections were analyzed
using an inverted light/fluorescence microscope and com-
pared to native tissues (ZEISS Axiovert 40 CFL and ZEISS
Axioplan II; Carl Zeiss AG).
Quantitative explant tissue analysis
TEVV constructs (n = 14 representative samples) were
minced, lyophilized, and analyzed using biochemical assays
for total DNA content as an indicator for cell number, hy-
droxyproline (HYP) content as an indicator for collagen, as
well as for glycosamnioglycan (GAG) content. For mea-
suring the cellularity of the constructs, the DNA amount was
quantitated according to an established protocol.20 Briefly,
papain-digested samples were incubated with Hoechst dye
at final concentration of 2.5 nM (Bisbenzimide H 33258;
Fluka) for 10min at room temperature protected from light.
Resulting fluorescence was quantified and compared to
standards made of calf thymus DNA (Sigma Chemical Co.)
with a fluorometer (Fluostar; BMG, 355 nm excitation/
460 nm emission). The GAG content was determined using
a modified version of the protocol described by Farndale
et al.21 and a standard curve was prepared from chondroitin
sulfate from shark cartilage (Sigma Chemical Co.) in addi-
tion to the samples. Briefly, the GAG amount was deter-
mined colorimetrically using di-methyl-methylene blue
stain [DMMB: 46mM 1,9-di-methyl-methylene blue,
40.5mM Glycin, and 40.5mM NaCl (pH 3)], following
complete papain digestion of the constructs in digestion
buffer [100mM sodium phosphate (pH 6.5), 5mM L-
cysteine, 5mM EDTA, and 125mg/mL papain (Sigma)] in a
4:15 ratio of sample:DMMB. The absorbance was measured
at 540 and 595 nm; the values obtained at 595 nm were
subtracted to the ones of 540 nm.
The amount of collagen (HYP) was determined with a
modified version of the protocol provided by Huszar et al.22
Briefly, minced tissue samples were hydrolyzed in NaOH
(Fluka) at a final concentration of 4mM in an autoclave at a
temperature of 120C for 10min. The solution was neu-
tralized by adding an equal volume of 1.4M citric acid
(Fluka). Chloramin-T was added to a final concentration of
56mM and the samples were oxidized for 20min before
adding aldehyde/perchloric acid solution at a final concen-
tration of 0.5M. The chromophore was allowed to develop
at 65C for 15min. The absorbance of the obtained solutions
was determined at 550 nm. The amount of HYP present in
the hydrolysates was determined from a standard curve us-
ing known amounts of trans-4-hydroxy-L-proline (Sigma
Chemical Co.).
Grating interferometry
PGA-P4HB starter matrices as well as bioengineered
constructs—in crimped as well as uncrimped state—were
evaluated using grating interferometry (GI; n = 3). GI rep-
resents a hard X-ray imaging method that simultaneously
exploits absorption as well as phase information, the latter
typically providing superior contrast if applied to soft-tissue
samples.23–25 Experiments were performed at the TOmo-
graphic Microscopy and Coherent rAdiology experimenTs
(TOMCAT) beamline of the Swiss Light Source (Villi-
gen).26 Optimal sensitivity toward density variations was
ensured by choosing a photon energy of 25 keV and an in-
tergrating distance of 121mm.27 Samples were embedded in
2% agarose gel within an Ependorff cylinder for mechanical
fixation. Tomography scans were performed with 1081
projections over 180 and five-phase steps. Total scan time
was *1 h. Tomographically reconstructed multislice infor-
mation was combined in three-dimensional images and
different stages of sample development were compared.
Scanning electron microscopy
Representative samples of the TEVV leaflet and conduit
areas of all (crimped and uncrimped) groups were fixed in
2% glutaraldehyde for > 24 h. After preparation, samples
were sputtered with gold and investigated using a Zeiss
Supra 50 VP Microscope (Zeiss).
Simulated delivery and crimping analysis
For evaluation of the effect of the delivery procedure on
the structural integrity of the mesenchymal stem cell–based
bioengineered venous valves, the constructs were crimped
using a commercially available crimping machine (n = 19;
Edwards LifeSciences, Inc.). For crimping of MSC-based or
endothelialized constructs the radial diameter of the stent
was reduced from 12.0mm down to*5.0mm (16 F) before
being introduced into the catheter system with a final di-
ameter of 8.0mm prior to deployment. The constructs were
crimped for 7min (mesenchymal stem cell group) or 10min
(EC group) and then deployed by pushing the valves out of
the sheath system (n = 7; see Fig. 2e–f).
Statistical analysis
The results on the quantification of ECs are presented as
mean – standard deviation. For the statistical comparison of
crimped versus non-crimped TEVV samples [IVIS analy-
sis and extracellular matrix (ECM) analyses] an unpaired T-
test was performed (SPSS 17.0; IBM). For comparing the
percental cellular loss with each group (signal loss per
leaflet) a paired T-test was performed (SPSS 17.0; IBM).
Biochemical measurements are presented as mean – stan-
dard error of the mean. A p-value < 0.05 was considered
statistically significant (SPSS 17.0; IBM and Microsoft
Office Excel 2007; Microsoft, Inc.).
Results
Morphology and phenotype of ovine bone
marrow–derived mesenchymal stem cells
Outgrowing ovine BM-MSCs (oMSCs) expressed myo-
genic markers, such as a-SMA and vimentin (Fig. 1c–e).
Desmin—another common smooth muscle cell marker—
was not expressed in expanded oMSCs (Fig. 1f). In im-
munohistochemistry oMSCs revealed expression of several
ovine (mesenchymal) stem cell markers, such as CD29 or
CD44, STRO-4, and CD166, while no positive signal was
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found for vWF, CD31, and isotype controls (Fig. 1b, g).
Flow cytometric analysis revealed high expression levels for
CD29, CD166, CD44, and also STRO-4; however, no ex-
pression of CD31 could be detected in oMSCs (Fig. 1a).
Analysis of TEVVs: macroscopic appearance
After successful isolation, oMSCs were expanded and
seeded onto PGA-P4HB composite scaffolds for static (up to
7 days) and dynamic conditioning (up to 14 days). Static
control constructs were cultured under nondynamic envi-
ronment for up to 3 weeks and harvested accordingly
(n= 41). The bi- and trileaflet-valve-shaped constructs were
intact, pliable, and mobile (Fig. 2a–f) after dynamic (pul-
satile) conditioning in a bioreactor system with neotissue
densely covering the bioengineered valves independent of
the conditioning protocol used. After harvest, the fused bi-
and trileaflet structures (Fig. 2a–c, f) were successfully
FIG. 1. Immunohisto-
chemical phenotype of ovine
bone marrow–derived mes-
enchymal stem cells
(oMSCs). Isolated adherent
ovine MSCs show positive
signals for CD166, CD44,
CD29, and STRO-4 in flow-
cytometry analysis (a). No
signal was detected for CD31
(a; IgG1 served as isotype
control). In immunohisto-
chemistry (b–g), oMSCs
show expression of myogenic
markers (c–e), including
alpha-smooth muscle actin
(a-SMA) (c, d) and vimentin
(e). Also stainings for com-
mon ovine stem cell markers
(b), including CD29, CD166,
STRO-4, and CD44, are
positive (b; scale bar= 16
mm). No positive signal was
found for CD31 (b), IgG1-
isotype control, Desmin (f),
and von Willebrand factor
(vWF) (g). Color images
available online at www
.liebertpub.com/tec
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separated from each other (Fig. 1d, e) using a scalpel
without laceration of the constructs. Separated TEVV con-
structs were then successfully used for crimping and/or
simulated delivery analysis (Fig. 2g–i).
Qualitative tissue analysis: histology
and immunohistochemistry
Tissue-engineered constructs grown under static condi-
tions (control constructs; n = 41) demonstrated cellular in-
growth but little tissue formation and production of ECM in
Trichrome-Masson staining (Fig. 3k, l). In contrast, con-
structs of all (long term) dynamic groups (7/14 days)
showed layered tissue arrangement in H&E staining (Fig.
3a, b) and substantial tissue formation with production of
ECM in the conduit wall (Fig. 3c, d) as well as in the TEVV
leaflet structures (Fig. 3e, f). In detail, Trichrome-Masson
staining highlighted collagen formation at the outer (lumi-
nal) layers of TEVVs (Fig. 3c, a), whereas in the center,
loosely arranged ECM with scaffold remnants was detect-
able (Fig. 3c, b; arrows in Fig. 3c, d represent residual
scaffold fibers). a-SMA-positive cells were present in
superficial layers of both, static and dynamic, constructs
(Fig. 3g–h).
Crimping analysis: ECM
For quantitative assessment of the ECM components,
biochemical assays for the determination of the DNA, GAG,
and HYP were performed for different cultivation time
points and crimping stages. Following in vitro conditioning,
all groups—independent of the crimping stage—showed
GAG values comparable to native. When comparing GAG
values of crimped versus uncrimped samples, no significant
differences were found ( p > 0.05; see Fig. 4a). Also the
cellularity did not differ significantly between crimped and
uncrimped samples ( p > 0.05; see Fig. 4b). For HYP the
values were substantially lower than the native control and
also showed no significant differences between crimped and
uncrimped tissues ( p > 0.05; see Fig. 4c).
Crimping analysis: macroscopy and histology
after simulated delivery
TEVVs (n= 18) were crimped using a commercially
available crimping device, introduced into a delivery system
(n = 7), and deployed (experimental delivery). Histological
analysis after crimping and simulated delivery included
comparison after crimped (n = 18) versus uncrimped (n= 9)
TEVVs (Fig. 5b–f). Trichrome-Masson staining revealed
integrity of the a-SMA-positive luminal collagen layer after
crimping and simulated delivery. No signs for impairment
of the construct integrity on the histological level—such as
holes, fissures, or fractures—could be identified. However,
this assessment is significantly limited as to the two-
dimensional character of the analysis. Also, macroscopically
no signs of impairment or inhomogeneity could be identi-
fied. However, on the macroscopic level, the aspect of lower
coadaptation of the leaflets (radial leaflet length shortening)
was observed when compared to the precrimping state.
Crimping analysis: scanning electron microscopy
After crimping (and simulated delivery) of (non-
endothelialized) TEVVs, surfaces were analyzed using
scanning electron microscopy (SEM). In SEM the cells re-
vealed homogenous orientation in several regions (Fig. 6a–j);
however, no consistent cell arrangement was observed
through the entire constructs as to the complex diastolic
valvular flow profile of this (flow pulse duplicator) bioreactor
system. Similar to histology, also SEM revealed no struc-
tural impairment, such as cracks or holes, on the crimped
FIG. 2. Macroscopy of tis-
sue-engineered bi- and tri-
cuspid venous valves.
Tricuspid (a–e) and bicuspid
(f) tissue-engineered venous
valves (TEVVs) were fabri-
cated using a diastolic (flow)
pulse duplicator system (a–f:
scale bar= 5mm). After
harvest, the fused leaflets
(a–c, f; c: inferior view; f,
arrow = value opening) were
separated (d, e) and a series
of valves was crimped and
inserted into a delivery de-
vice (g–i: scale bar = 4mm;
h: arrow = crimping forces;
asterisk = leaflets). Color
images available online at
www.liebertpub
.com/tec
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(Fig. 6f–j) versus the uncrimped construct surfaces (Fig. 6a–e).
However, in some regions of the crimped constructs, ‘‘bare’’
PGA fibers (not covered with cells) could be identified (Fig.
6h; arrows), whereas in the matching uncrimped controls,
PGA fibers were densely covered by seeded oMSCs (Fig.
6e; arrows). However, given the limited number of samples,
these qualitative findings require further confirmation and
quantitative assessment in future experiments. Besides this
aspect, no changes on the cellular level on the construct
surfaces could be identified in SEM.
Grating interferometry
For three-dimensional analysis of in vitro tissue formation
and degradation of the composite starter matrix and—
importantly—for the assessment of three-dimensional
crimping effects, a series of three constructs was investi-
gated using GI. GI samples comprised unconditioned (un-
seeded) PGA-P4HB starter matrices, and TEVVs in crimped
and uncrimped states. In comparison to the unconditioned
scaffold constructs (Fig. 7a–d), the conditioned TEVV
samples (Fig. 7e–l) revealed clear tissue formation embed-
ded into remnants of the PGA-P4HB scaffold meshwork.
The signal for the composite scaffold was reduced after
14 days of dynamic conditioning (Fig. 7e–h), suggesting
degradation of the composite starter matrix components
as confirmed by histology (Fig. 3a–f). As previously re-
ported,19 in the three-dimensional GI reconstruction, the
degradation was inhomogeneous with zones of higher versus
lower degradation (Fig. 7f, h: blue lines indicate zones
of higher degradation). This suggests a cluster-like (in-
homogeneous) tissue maturation within the bioengineered
TEVVs. The crimped bioengineered construct showed a
similar inhomogeneous, cluster-like matrix composite deg-
radation. Using a manual segmentation approach (repre-
sentative segmented slices are shown in Fig. 7g–k) the
proportions of scaffold versus biological matrix were
quantified revealing that the proportion of biological matrix
did not undergo substantial volumetric changes during the
crimping procedure (matrix ratio at precrimping state:
76%– 6% versus matrix ratio at postcrimping state:
83%– 2%). In spite of the lack of clear changes regarding
FIG. 4. Biochemical extracellular matrix
(ECM) analysis. Analysis for ECM compo-
nents revealed no significant differences for
glycosaminoglycans (GAG; a), DNA (b),
and hydroxyprolines (HYP; c) when com-
paring uncrimped (A) versus crimped (B)
constructs (values: % of native control;
mean – SEM; ** = p < 0.05).
FIG. 3. Histological analysis of TEVVs. Dynamic TEVV constructs showed layered tissue arrangement in hematoxylin and
eosin (H&E) staining (a, b) with surface-mediated collagen formation visible in Masson-Trichrome staining in the conduit
wall (c, d; collagen matrix: a; subcollagen nondegraded scaffold zones: arrow and b) and the leaflet (e, f). In the wall area,
also a-SMA-positive regions were found (g–h) with no positivity for Desmin (i, j). In static (nondynamic control) constructs
only a small band of cells (close to the surface) could be identified (k, l). (a–f, k, l: 10·magnification, scale bar*100mm; g,
i: 20· , scale bar *50mm; h, j: 40· , scale bar *25mm). Color images available online at www.liebertpub.com/tec
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the ECM portions of the bioengineered matrix, the distri-
bution of the matrix was less homogeneous when compared
with the precrimping state (see Fig. 7h, l; red and blue lines).
These changes in the matrix could be due to the tissue
compaction effects throughout the crimping procedure or
represent artifacts of the inhomogeneous degradation be-
havior. However, given the complexity of the analysis and
the low sample number, this finding needs further evaluation
by future experimental studies.
Crimping analysis using planar fluorescence
reflectance scanning
As part of the conventional in vitro tissue engineering
approach, MSC-based matrices are endothelialized prior to
in vivo implantation. However, in case of minimally inva-
sive delivery, the crimping may impair the integrity of the
vulnerable EC coverage on the TEVV surface. For assess-
ment of the loss of ECs a representative series of bicuspid
(n = 6) as well as tricuspid TEVV leaflets (n = 15) was see-
ded with cryopreserved ovine CFSE-labeled ECs (see Fig.
8a–d). After static in vitro incubation the valves were
crimped using a clinically relevant protocol (10min, *16
F) and the loss of CFSE signal was quantified using a planar
fluorescence reflectance CCD camera. As shown in Figure 8
the CSFE signal per leaflet (Fig. 8e) was reduced signifi-
cantly [reduction for protocol (1) 73.8%– 25.9% and for
protocol (2) 51.49%– 19.8%; Fig. 8f; all p’s < 0.001] during
the crimping procedure, while unseeded leaflets showed no
significant reduction of the fluorescence in the leaflets (re-
duction of 10.5% – 13.6%; Fig. 8f; p > 0.05). These results
suggest that there is a significant loss of ECs during the
crimping procedure of TEVVs. However, interestingly the
cellular loss was significantly different between the different
static incubation protocols (1) and (2) ( p < 0.001), suggest-
ing further that longer static incubation prevents cellular loss
of ECs during crimping (Fig. 8d).
Discussion
CVI is a common pathology of the cardiovascular system
and represents a global health problem.5 In the United
States 10–35% of the adult population is affected and these
numbers are expected to increase in the future given the
demographic development.7,28 CVI is caused by an incom-
petence of the venous valves, which causes retrograde ve-
nous flow (reflux) with distal venous hypertension and a
plethora of further sequela.29 Treatment of CVI is domi-
nated by nonsurgical modalities, which are mainly of pal-
liative nature and are deemed ineffective of changing the
underlying cause of the disease. Therefore, several surgical
and—in the recent years—interventional experimental ap-
proaches have focused on the replacement of the diseased
valvular structures using prosthetic venous valves. Since the
FIG. 5. Histological analysis of crimped
versus uncrimped TEVV constructs. The
histological analysis of three individual
bioengineered venous valves before (a, c, e)
and after (b, d, f) crimping (Masson Tri-
chrome) showed layered tissue formation
with collagen-rich elements close to the
surface of the bioengineered constructs in
both groups (a–f). In the group of crimped
samples no signs of surface laceration,
cracks, holes, or other signs of structural
impairment could be identified on the his-
tological level (b, d, f) (scale bar = 100 mm).
Color images available online at www
.liebertpub.com/tec
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mid-60s several different valve prostheses have been in-
vestigated on the experimental and clinical level involving
single-, double-, or trileaflet designs, and involving allo-
genic, xenogenic, or synthetic materials.7,30,31 Initial clinical
attempts that focus on cryopreserved homografts showed
poor clinical outcomes with rejection of the transplanted
valves, leading to high morbidity and occlusion rates.32 This
stimulated the development of autologous transplantation
strategies in order to prevent graft rejection complications.
Although some of these approaches showed promising ex-
perimental33,34 and clinical results,35,36 several approaches
were limited by the lack of adequate or sufficient amounts of
autologous replacement structures.7
Cardiovascular tissue engineering could overcome these
limitations by providing autologous cell-based replacement
structures with absence of immunogenic rejection.8,9 The
concept of cardiovascular tissue engineering is based on
biodegradable scaffold materials that are seeded with au-
tologous cells and cultured under native-like flow conditions
in vitro to generate native-analogous tissue-engineered
FIG. 6. Scanning electron microscopy
(SEM) analysis of crimped versus un-
crimped TEVV constructs. SEM analysis of
uncrimped samples revealed confluent cov-
erage of the bioengineered constructs by
oMSCs (a–d) with cells densely covering
polyglycolic acid (PGA) fiber components
(e; arrows = PGA fibers). This confluent
cellular coverage of the surface remained
unchanged throughout the crimping proce-
dure (f, g, i, j); only in some areas un-
covering of PGA fiber elements was
observed (h; arrows) not evident in the
uncrimped samples (e; arrows).
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constructs.9 In particular in the field of heart valve regen-
eration, several recent preclinical large animal trials in-
volving sheep14,15,17 and non-human primate models16
showed promising initial results and underline the potential
of this technology for future therapeutic concepts.
Given the major complications when using xeno- or
homogenic venous valve transplants, Teebken et al.37 in-
vestigated for the first time TEVVs based on a homologous
decellularized matrix in the ovine model. After removal of
cellular elements, the valves were repopulated with autolo-
gous myofibroblasts and implanted into the external jugular
veins with patency up to 12 weeks. In spite of promising
short-term results, also in these homologous reseeded con-
structs, immunologic rejection phenomena were observed
with inflammation and neointima formation being evident in
the TEVV explants.37 In addition, the widespread issue of
scarcity of human donor organs available for transplanta-
tion38 severely limits a widespread application of concepts
based on healthy human homologous transplants for treat-
ment of such frequent pathologies.
Therefore, the present study investigates for the first
time the fabrication of BM-MSC-derived miniaturized
TEVVs based on a synthetic, completely biodegradable
PGA-P4HB composite matrix. Given their fully autologous
nature, these living patient cell–derived constructs hold the
potential to overcome the limitations of immunogenic re-
jections reported for xenogenic or homogenic transplants
and are not dependent on the availability of human healthy
donor tissue.
However, in recent years the field of heart valve and also
venous valve implantation has encountered a major tech-
nological revolution with development of percutaneous
low-invasive delivery techniques.39 In venous valve repair
several clinical trials have been initiated using percutaneous
transcatheter delivery methods. Borst et al. reported clinical
phase I and II trials using glutaraldehyde-fixed bovine jug-
ular valve–based venous xenografts integrated into a nitinol
stent for transcatheter implantation.40–42 Also the group of
Pavcnik et al. reported a minimally invasive transcatheter ap-
proach based on a xenogenic bioprosthetic venous valve sys-
tem with initial promising results.43–45 Therefore, besides the
use of an autologous low-invasive cell source (such as BM-
MSCs), a clinically relevant TEVV concept requires a com-
bination of the tissue engineering technology with minimally
invasive delivery methods, which has already been success-
fully demonstrated for heart valve tissue engineering in the
ovine model for the low-14 as well as the high-pressure sys-
tem17 up to 2 months in vivo. Recently, stented TEHVs could
also be minimally invasively delivered into the orthotopic
pulmonary position of a clinically relevant non-human primate
model that shows promising results in vivo with confluent
endothelialization and interstitial valve remodeling.16
Also in the present study adequate tissue formation was
achieved using a diastolic pulse duplicator system with
FIG. 7. Grating interfer-
ometry (GI) of TEVV con-
structs. GI analysis of PGA–
poly-4-hydroxybutyrate
(P4HB) starter matrices
showed homogeneous scaf-
fold networks (a–d; uncon-
ditioned bare scaffold
material). After dynamic
in vitro conditioning (condi-
tioned samples: e–l) inho-
mogeneous degradation of
the scaffold matrix was
observed (blue lines indicate
major degradation zones;
e–h). After crimping of the
construct, the aspect of
‘‘shifting’’ of the ECM
components could be ob-
served with areas of biologi-
cal matrix accumulation and
areas with less matrix present
(i–l; red line: area without
substantial neomatrix pres-
ent). [Pre-CRI = before
crimping; Post-CRI = after
crimping]. Color images
available online at www
.liebertpub.com/tec
10 WEBER ET AL.
layered collagen arrangement, increasing glycosaminogly-
can content and surface endothelialization. However, as
previously reported for bioprosthetic valves,46 the crimping
and minimally invasive delivery procedure may affect the
viable tissue components of the bioengineered venous
valves. Therefore, representative numbers of BM-MSC-
derived crimped and uncrimped TEVV constructs were
analyzed using SEM, histology/immunohistochemistry, GI,
and biochemical ECM analysis. Neither SEM nor histo-
logical analyses revealed lacerations or changes of the
TEVV constructs during the crimping procedure, also no
compression effects were observed as reported by previous
studies that focus on human-cell-based constructs.19 GI, a
novel tool for 3D analysis of tissue-engineered constructs,
showed inhomogeneity of the ECM arrangement in the
crimped sample; however, these results were limited by
the low sample number (n = 3) of this pilot analysis and the
influence of inhomogenous degradation/tissue formation
remains unclear. As reported in a previous study,19 some
minor changes in the biochemical ECM parameters were
observed; however, none of those changes were statistically
significant. These results suggest that the BM-MSC-derived
bioengineered tissue component of the TEVV constructs
was not affected by the crimping procedure on the structural
level. This finding is supported by previous experiments that
focus on tissue-engineered occluder membranes, which also
showed no significant changes after crimping on the mes-
enchymal/fibroblastic cell level. However, in these studies19
morphological changes were reported for the EC level in
scanning ion conductance microscopy. Therefore, in the
present study, we endothelialized a series of TEVV samples
with CFSE-labeled cryopreserved ovine ECs and measured
the cellular loss during the crimping procedure using the
IVIS system. This revealed that crimping (10min;*5mm)
did not significantly change the overall DNA amount in the
constructs but resulted in a significant loss of ECs (*74% of
initially seeded cells) on the surface. This suggests that see-
ded EC monolayers may represent the ‘‘weakest’’ part of
bioengineered constructs exposed to crimping procedures.
When considering recent experimental results, the relevance
of this EC loss seems unclear. First, because implantation of
non-endothelialized heart valve constructs into non-human
primates resulted in almost confluent endothelialization al-
ready after 4 weeks in vivo,16 and second, because novel
approaches completely circumvent the endothelial compo-
nent and focus on the implantation of decellularized and/or
FIG. 8. Planar fluorescence reflectance imaging analysis of crimped TEVV constructs. TEVVs were seeded with CFSE-
labeled endothelial cells (ECs) that stained positive for vWF (a; green = vWF, blue =DAPI, red = phalloidin; b = isotype
control). After seeding (stereomicroscopy analysis of the ECs on the leaflet; c, d; scale bar= 500 mm) the valves were
crimped (for 10min, *5mm) and the fluorescence signal was measured before and after crimping (e; V1–V3 show three
representative examples). When quantified, the fluorescence in the seeded constructs decreased during the crimping pro-
cedure, while the fluorescence signal of unseeded control areas remained unchanged (f). Interestingly, the cellular loss
significantly decreased when increased static conditioning periods were used, indicating that adapted protocols may prevent
the EC loss (f) (scale bars: a, 16mm; b, 25mm). Color images available online at www.liebertpub.com/tec
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reseeded tissue-engineered constructs for heart valve regen-
eration.47 In addition, the loss of ECs during the crimping
procedure could be significantly reduced by increasing the
static in vitro conditioning phase. However, the loss of ECs
and the associated thrombogenicity certainly represents a
major question to be answered in future preclinical in vivo
animal trials as the lack of major thrombogenicity displays an
indispensable prerequisite for a possible clinical translation of
the involved technology.
In conclusion, this feasibility in vitro study successfully
combines two evolving technologies, that is, cardiovascular
in vitro tissue engineering as well as minimally invasive
valve replacement techniques. The presented data shows
that the in vitro fabrication of miniaturized living tissue-
engineered valves based on autologous (mesenchymal) stem
cells and on fully biodegradable (composite) polymer
scaffolds integrated into nitinol stent systems is feasible in
the ovine model and lays the foundation for an animal
in vivo trial in the near future. These upcoming in vivo ex-
periments will have to carefully assess the leaflet function-
ality as well as the in situ remodeling of the TEVV
constructs in order to bring the technology closer to a pos-
sible future clinical translation.
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